Ypsomed has sold its subsidiary Ypsotec AG to Callista Asset Management to focus on its core business of self-injection medical technologies.

Overview of the Target

Ypsomed AG has successfully completed the sale of its subsidiary, Ypsotec AG, to Callista Asset Management 32 GmbH on October 31, 2025. This transaction marks a significant strategic shift for Ypsomed, which aims to concentrate more on innovative medical technology solutions for self-injection therapies. The divestiture allows Ypsomed to enhance its financial flexibility, enabling the company to accelerate its research, development, and market introduction of new therapeutic solutions.

Industry Overview in Switzerland

The Swiss medical technology sector is recognized as one of the leading industries, characterized by high levels of innovation and a robust regulatory environment. This industry is driven by a strong demand for advanced medical devices, particularly in areas such as diabetes management and other chronic disease treatment solutions. The country's unique combination of scientific expertise, cutting-edge research facilities, and a skilled workforce has fostered an ecosystem conducive to the growth of medical technology companies.

Furthermore, Switzerland's commitment to maintaining high standards of healthcare and technology has positioned it as a hub for innovation, attracting investment and talent from around the globe. With a high